The shares of Evolva Holding ("Evolva") are traded on the SIX Swiss Stock Exchange (ticker: "EVE").
This presentation may contain specific forward-looking statements, relating to Evolva's future business, development and economic performance. e.g., statements including terms like "believe", "assume", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Evolva and those explicitly or implicitly presumed in these statements.
Against the background of these uncertainties, readers should not rely on forward-looking statements.
Evolva assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Back to accelerated growth path despite challenging environment. Gross profit positive from Q4, 2021
• Total revenue grew 60% compared to previous year reaching CHF 6.4m, in line with plans
• Ongoing momentum in Health Ingredients. Increased sales in Flavors and Fragrances raised hope of a market recovery. Stevia royalty income is showing an accelerating growth trajectory.
• Investments in the expansion of the contract manufacturers network, scale up of manufacturing and optimization of manufacturing processes started to produce positive results. The company expects to be gross profit positive across products from Q4, 2021
• Excluding extraordinary costs of CHF 1.0m related to manufacturing, first half 2021 adjusted EBITDA
loss came in at CHF -12.0m, driven by higher manufacturing costs (CHF +4.8m)
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Evolva Holding SA published this content on 10 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2021 12:01:01 UTC.
Evolva Holding Ltd is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.